$CAI

Caris Life Sciences (NASDAQ: CAI) published a study in npj Precision Oncology on an AI tool for pancreatic cancer treatment. The tool, part of the Caris Molecular Tumor Board Report, predicts patient outcomes for two treatments, with median survival of 16 months for FOLFIRINOX vs. 9.9 months for gemcitabine plus nab-paclitaxel. The company's MI Cancer Seek test, FDA-approved in November 2024, includes this tool.

Caris Life Sciences (CAI) stock rose 73% from its May low, closing at $24.58 on August 20. The rally followed record revenue of $263.71 million and raised full-year guidance. Analysts' target prices range from $25 to $36, with a mid-target of ~$25. Management highlighted potential margin expansion due to cost reductions and pricing gains, but the stock trades at 86x forward earnings, indicating high valuation.

Journey Medical (DERM) rose 13% on strong Q2 results, with revenue up 23% to $18.5M. Iovance (IOVA) gained 11% on 66% revenue growth to $99.3M. Caris (CAI) advanced 8% after raising 2026 revenue guidance to $1.03B-$1.04B. Prelude (PRLD) up 8% on narrower Q2 loss. Compugen (CGEN) gained 7% on COM701 trial progress. Conexeu (CNXU) rose 4% on regenerative aesthetics market opportunity.

The article lists recent tech M&A deals. Citigroup will acquire Kard Financial to bolster U.S. credit card rewards technology; terms were not disclosed and Citi said it is not material. CAI Software will buy LLumin to add predictive maintenance and asset management capabilities; terms not disclosed. Providence Equity will acquire Hometrack from ZPG to expand property data software.

Caris Life Sciences (Nasdaq: CAI) reported Q2 2026 revenue of $263.7 million, up 45% year over year, driven by 55% growth in molecular profiling services to $252.3 million. It completed about 59,200 clinical cases and posted 68% gross margin. 2026 revenue guidance was raised to $1.03 to $1.04 billion.

Caris Life Sciences (NASDAQ:CAI) shares rose up to 21.58% after Q2 results. The company cut net loss attributable to shareholders to $637,000 from $517.2M, while revenue rose 45% to $263.7M. Molecular profiling services revenue increased 55% to drive growth. Caris forecasts 2026 revenue of $1.03B-$1.04B and 26.8%-28% growth, and reaffirmed therapy selection volume growth guidance.

Caris Life Sciences said a study in Cancer Research Communications used a multimodal deep learning model combining digitized H&E pathology images and clinical data to estimate late distant recurrence risk in HR+ early breast cancer. It was trained on 2,271 NSABP B-42 patients and validated on 4,300 TAILORx specimens, showing about an 8% 10-year risk gap between model high and low groups and suggesting greater benefit from extended letrozole in high-risk patients.

Caris Life Sciences, Inc. (CAI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance Revenue growth of 45% driven by strong performance in molecular profiling services, including approximately 59,200 clinical cases, consisting of over 114,000 whole e

Investing.com reports BTIG analyst Mark Massaro previewed seven specialty labs and diagnostics stocks as valuations rise. BTIG rates Guardant Health (GH) Buy, $190 target; Natera (NTRA) Buy, $290; BillionToOne (BLLN) Buy, $142; GeneDx (WGS) Buy, $90; Adaptive Biotechnologies (ADPT) Buy, $24; Tempus AI (TEM) Buy, $80; Caris (CAI) Buy, $32, with Q2 expectations and volume or catalyst updates.

Investing.com reported Monday insider trading filings. Energizer (ENR): reporting owners bought 60,000 shares for about $1.23M at ~$20.20-$20.75. Gloo (GLOO): Grace & Mercy Foundation bought 923,076 shares for ~$3.00M. IPERIONX (IPX): CEO and chairman bought shares totaling about $2.38M. Arista (ANET): CEO sold 242,422 shares for ~$45.6M. Dell (DELL): Silver Lake sold about 124,598 shares for ~$58.1M.